Mackay Shields LLC Allakos Inc. Transaction History

Mackay Shields LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$85.37 - $114.1 $845,163 - $1.13 Million	-9,900 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$109.73 - $153.66 $669,353 - $937,326	-6,100 Reduced 38.13%	9,900 $1.14 Million
Q4 2020 Feb 16, 2021	SELL	$79.58 - $152.45 $127,328 - $243,919	-1,600 Reduced 9.09%	16,000 $2.24 Million
Q3 2020 Nov 04, 2020	SELL	$66.43 - $90.99 $26,572 - $36,396	-400 Reduced 2.22%	17,600 $1.43 Million
Q2 2020 Jul 31, 2020	BUY	$44.04 - $80.69 $96,888 - $177,518	2,200 Added 13.92%	18,000 $1.29 Million
Q1 2020 May 08, 2020	BUY	$44.49 - $93.39 $186,858 - $392,238	4,200 Added 36.21%	15,800 $703,000
Q4 2019 Feb 11, 2020	BUY	$66.49 - $137.73 $771,283 - $1.6 Million	11,600 New	11,600 $1.11 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $91.5M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.